Frankfurt - Delayed Quote EUR

Syndax Pharmaceuticals, Inc. (1T3.F)

11.50

+0.30

+(2.68%)

As of 8:02:13 AM GMT+2. Market Open.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vestin

GlobeNewswire 20 days ago

SNDX
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in

GlobeNewswire 22 days ago

SNDX
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...

Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, despite facing operational and market challenges.

GuruFocus.com last month

SNDX
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -1.85% and 65.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

SNDX
Syndax: Q4 Earnings Snapshot

WALTHAM, Mass. AP) — Syndax Pharmaceuticals Inc. SNDX) on Monday reported a loss of $94.2 million in its fourth quarter.

Associated Press Finance last month

SNDX
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025

GlobeNewswire last month

SNDX
Syndax Announces Participation in March Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m.

GlobeNewswire last month

SNDX
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss

GlobeNewswire last month

SNDX
Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 2 months ago

SNDX
Syndax Announces Participation in February Investor Conferences

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

PR Newswire 2 months ago

SNDX
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs). Nik

PR Newswire 3 months ago

INCY

SNDX
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Syndax Pharmaceuticals (Nasdaq: SNDX) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th at 10:30 a.m. PT/1:30 p.m. ET. Ahead of the presentation, Syndax highlighted its recent accomplishments and anticipated 2025 milestones.

PR Newswire 3 months ago

SNDX
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain

It hasn't been the best quarter for Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders, since the share price...

Simply Wall St. 3 months ago

SNDX
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 10:30 a.m. PT/ 1:30 p.m. ET.

PR Newswire 3 months ago

SNDX
$Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial$

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced additional positive data from the AUGMENT-101 trial of Revuforj® (revumenib) in relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) and the BEAT AML trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed AML patients. Revuforj is the Company's oral, first-in-class menin inhibitor that is

PR Newswire 4 months ago

SNDX
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presented positive data from multiple trials of Revuforj® (revumenib) as a single-agent and in combination with standard of care agents in patients with acute leukemias in oral sessions at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, December 7-10, 2024. Revuforj is the Company's oral, first-in-class menin inhibi

PR Newswire 4 months ago

SNDX
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of Biotechnology The biotechnology sector is expanding […]

Insider Monkey 4 months ago

SNDX
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on novel mechanisms in oncology at the Citi 2024 Global Healthcare Conference on Thursday, December 5, 2024 at 11:00 a.m. ET.

PR Newswire 4 months ago

SNDX
FDA approves Syndax’s Revuforj to treat leukaemia

The approval is based on the Phase I/II AUGMENT-101 trial, which included 104 patients with acute leukaemia.

Pharmaceutical Technology 5 months ago

SNDX
$Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation$

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (ND

PR Newswire 5 months ago

SNDX

Performance Overview

Return	1T3.F	S&P 500 (^GSPC)
YTD	-3.36%	-6.75%
1-Year	-39.15%	+8.64%
3-Year	-23.84%	+27.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Syndax Pharmaceuticals, Inc. (1T3.F)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates

Syndax: Q4 Earnings Snapshot

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Syndax Announces Participation in March Investor Conferences

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Syndax Announces Participation in February Investor Conferences

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

FDA approves Syndax’s Revuforj to treat leukaemia

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Performance Overview